10-Q: Assertio Holdings Reports Q1 2025 Results: Revenue Declines Amid Generic Competition, Strategic Divestiture Announced

Assertio Holdings' Q1 2025 results reveal a revenue decrease due to generic competition and pricing pressures, alongside a strategic divestiture of Assertio Therapeutics to streamline operations.

Summary

• Assertio Holdings, Inc. reported a net loss of $13.541 million, or $0.14 per share, for the three months ended March 31, 2025, compared to a net loss of $4.510 million, or $0.05 per share, for the same period in 2024.
• Total revenue decreased to $26.488 million from $32.448 million year-over-year, primarily due to lower product sales.
• ROLVEDON net product sales decreased by $1.4 million to $13.1 million, while INDOCIN net product sales decreased by $3.1 million to $5.5 million due to generic competition.
• Selling, general, and administrative expenses increased by $3.5 million to $22.0 million, mainly due to higher legal charges and settlements.
• The company divested all equity interests in Assertio Therapeutics on May 9, 2025, expecting to record a loss of $8 million to $9 million in Q2 2025.
• The company's cash and cash equivalents and short-term investments totaled $87.3 million as of March 31, 2025.
• The company expects to meet its cash needs with existing cash, cash equivalents, and short-term investments.

Sentiment

Score: 4

Explanation: The sentiment is negative due to declining revenues, increased losses, and ongoing legal challenges. However, the company's efforts to streamline operations and manage cash flow provide some positive aspects.

Positives

• SPRIX net product sales increased slightly by $0.2 million to $1.6 million due to favorable payor mix.
• The company believes its existing cash and cash equivalents and short-term investments will be sufficient to fund operations for the next 12 months.
• The company is in compliance with its covenants with respect to the 2027 Convertible Notes as of March 31, 2025.
• The company settled a qui tam litigation matter for $3.6 million, removing uncertainty.

Negatives

• Net loss increased significantly year-over-year.
• Total revenues decreased due to lower product sales, particularly ROLVEDON and INDOCIN.
• INDOCIN sales are expected to continue to be negatively impacted by increasing generic competition.
• Selling, general, and administrative expenses increased due to higher legal charges and settlements.
• The company expects to record a loss on the Assertio Therapeutics divestiture.
• The company recorded a full valuation allowance against its net deferred tax asset as of both March 31, 2025 and March 31, 2024.

Risks

• Increased competition from generic products could further erode sales and profitability.
• Potential unfavorable outcomes in ongoing litigation could result in significant financial liabilities.
• Macroeconomic conditions, including inflation and interest rate changes, could negatively impact the business.
• Actions by activist shareholders could disrupt operations and increase costs.
• The company's common stock may not regain and maintain compliance with The Nasdaq Capital Markets minimum closing bid requirement of at least $1.00 per share.

Future Outlook

The company expects INDOCIN net product sales to continue to be impacted unfavorably by increasing competition as a result of existing generic entrants, new and expected future generic entrants, including two new generic entrants in 2025, and other competitive products. Due to the competitive markets in which our products compete, we expect the pricing of all of our products to be impacted by higher discounts, chargebacks, and rebates in the remainder of 2025 as compared to 2024.

Management Comments

• Management determined that our book value of equity exceeding our market capitalization represented an indicator of impairment with respect to its long-lived assets.
• Management maintains absolute discretion in determining the scope and impact of accomplishments as well as the final bonus payout for all employees.

Industry Context

The pharmaceutical industry is facing increasing pressure from generic competition, which is impacting the sales of branded drugs like INDOCIN. Companies are also facing increased scrutiny and litigation related to opioid products, leading to significant legal expenses and settlements.

Comparison to Industry Standards

• Assertio's performance is below par compared to industry leaders like Teva Pharmaceuticals and Mylan, which have successfully navigated generic competition through diversification and strategic acquisitions.
• The decline in revenue and increased net loss indicate that Assertio is struggling to maintain profitability in a challenging market environment.
• Compared to companies like Mallinckrodt and Purdue Pharma, Assertio's opioid-related legal liabilities appear to be less severe, but still pose a significant financial risk.
• The divestiture of Assertio Therapeutics is a strategic move similar to those made by other pharmaceutical companies to streamline operations and focus on core assets.

Corporate Governance

Legal Proceedings

• The company is involved in various lawsuits, claims, investigations and other legal proceedings that arise in the ordinary course of business.
• The company settled a qui tam lawsuit with the DOJ for $3.6 million.
• The company reached an agreement in principle to settle the Luo v. Spectrum Pharmaceuticals, Inc., et al. case for $16.0 million, with insurance covering the remainder.
• The company is defending itself in several stockholder actions, including Shapiro v. Assertio Holdings, Inc., et al., Edwards v. Assertio Holdings, Inc., et al., and In re Assertio Holdings, Inc. Derivative Litigation.
• The company is also defending itself in the Enyart v. Assertio Holdings, Inc., et. al. lawsuit.

Stakeholder Impact

• Shareholders: The decrease in revenue and increase in net loss may negatively impact shareholder value.
• Employees: Restructuring charges and workforce reorganization may lead to job losses and uncertainty.
• Customers: The divestiture of Assertio Therapeutics may impact the availability and support of certain products.
• Suppliers: Changes in supply agreements and purchase commitments may affect supplier relationships.

Next Steps

• The company expects all cash payments associated with restructuring undertaken in the first quarter of 2025 to be paid by the end of the third quarter of 2025.
• The company expects all cash payments under the Spectrum Reorganization Plan to be completed by the end of 2025.
• The company intends to vigorously defend itself in the Enyart v. Assertio Holdings, Inc., et. al. lawsuit and the Christiansen v. Spectrum Pharmaceuticals, Inc. et al lawsuit.
• The court has scheduled a hearing on the motion to dismiss the Enyart v. Assertio Holdings, Inc., et. al. lawsuit on June 4, 2025.

Key Dates

Keywords

Assertio Holdings, financial results, ROLVEDON, INDOCIN, generic competition, divestiture, litigation, revenue, net loss, Q1 2025